Latest Content

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.

Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.

Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.

Phil Rainey, OD, MPH, FAAO, states that the recent parameter expansion of Johnson & Johnson's Acuvue Oasys Max 1-Day and Oasys 1-Day has been a game changer for his practice.

A pair of cases from Academy 2026 show scleral lens refits for severe keratoconus, one addressing focal corneal edema and one fitting around glaucoma tube shunts.

Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.

Jade Coats, OD, FAAO, stopped by to discuss her presentation at AAOpt 2026, titled "How Eyelid Hygiene Can Change the Dry Eye Conversation."

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, details a lack of research exploring the intersection of hormones and ocular health in women and what health care as a whole should investigate next.

Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.

Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.

Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."